Cooley: Adaptive Phage Therapeutics Enters Into Definitive Merger Agreement With BiomX
March 08, 2024
March 08, 2024
RESTON, Virginia, March 8 -- Cooley, a law firm, issued the following news release:
Cooley advised Adaptive Phage Therapeutics (APT), a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX (NYSE: PHGE), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria.
Lawyers C . . .
Cooley advised Adaptive Phage Therapeutics (APT), a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX (NYSE: PHGE), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria.
Lawyers C . . .